Abstract | OBJECTIVE: METHODS: RESULTS: All patients were well tolerated to the regimen without serious drug related toxicity. Transplant related mortality were 0 and 4.3% at day 100 and one year. All patients except one got full donor engraftment and achieved complete remission. Acute GVHD was observed in 6 patients (26.1%) including grade III-IV in 5 patients. Chronic GVHD was reported in 15 of 21 evaluable patients (71.4%). With a median follow-up of 1138 (55-1747) days, 16 of 23 patients were alive and disease-free. Three-year overall survival (OS) and event free survival (EFS) were 79.2% and 69.6%, respectively. CONCLUSION: Modified Bu/Flu as a new RIC regimen is well tolerated and safe for patients who need allogeneic hematopoietic stem cell transplantation, especially in older patients and/or patients with severe comorbidities.
|
Authors | Feng-rong Wang, Xiao-jun Huang, Dai-hong Liu, Huan Chen, Yu Wang, Fei-fei Tang, Yu-qian Sun, Hai-xia Fu, Kai-yan Liu, Lan-ping Xu |
Journal | Zhonghua nei ke za zhi
(Zhonghua Nei Ke Za Zhi)
Vol. 52
Issue 12
Pg. 1028-32
(Dec 2013)
ISSN: 0578-1426 [Print] China |
PMID | 24503400
(Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vidarabine
- Busulfan
- fludarabine
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Busulfan
(administration & dosage)
- Child
- Female
- Hematologic Neoplasms
(drug therapy, therapy)
- Hematopoietic Stem Cell Transplantation
- Humans
- Male
- Middle Aged
- Transplantation Conditioning
(methods)
- Vidarabine
(administration & dosage, analogs & derivatives)
- Young Adult
|